Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent

查看全文 作　　者：Aydin [1]Huseynov;Michael [1]Behnes;Uzair [1]Ansari;Stefan [1]Baumann;Dirk [1]Lossnitzer;Ibrahim El-[1]Battrawy;Christian [1]Fastner;Martin [1]Borggrefe;Ibrahim [1]Akin 机构地区：[1]First Department of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg 出　　处：《Journal of Geriatric Cardiology》索引2019年第16卷第11期,共4页 摘　　要：The COMBO stent(OrbusNeich Medical BV,the Netherlands)is a stainless-steel platform with the biodegradable abluminal coating containing antiproliferative sirolimus(5 mg/mm)and the luminal stent surface covered with anti-CD-34 antibody.The CD-34 antibodies essentially capture endothelial progenitor cells resulting in rapid re-endothelialization of the treated segment. 关 键 词：ADVERSE events ANTIPLATELET THERAPY COMBO STENT